Results 11 to 20 of about 72,871 (224)
A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. [PDF]
Clin Transl SciABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Gerhart J +7 more
europepmc +2 more sources
Разработка и регистрация лекарственных средств, 2022 Introduction. Many of new active pharmaceutical ingredients (APIs) have low solubility that can affect bioavailability negatively and therefore therapeutically efficacy as well.
S. A. Zolotov +4 more
doaj +1 more source
Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
Разработка и регистрация лекарственных средств, 2023 Introduction. SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) is expected to remain a persistent global threat. Therefore, development of coronavirus disease 2019 (COVID-19) drugs is the most urgent global issue.
T. N. Komarov +7 more
doaj +1 more source
BMC Infectious Diseases, 2017 Background Atazanavir/ritonavir and darunavir/ritonavir are common protease inhibitor-based regimens for treating patients with HIV. Studies comparing these drugs in clinical practice are lacking.
Tony Antoniou +14 more
doaj +1 more source
Metabolic and cardiac adaptation to chronic pharmacologic blockade of facilitative glucose transport in murine dilated cardiomyopathy and myocardial ischemia [PDF]
, 2018 GLUT transgenic and knockout mice have provided valuable insight into the role of facilitative glucose transporters (GLUTs) in cardiovascular and metabolic disease, but compensatory physiological changes can hinder interpretation of these models.
Heitmeier, Monique R. +6 more
core +2 more sources
Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy [PDF]
, 2003 Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Abdurrahman, Z. +10 more
core +2 more sources
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
AIDS Research and Therapy, 2005 Background Protease inhibitors, particularly ritonavir, causes significant gastrointestinal disturbances such as nausea, even at low doses. This ritonavir-induced nausea could be related to its oxidative stress in the gut.
Chang Wei-Tien +5 more
doaj +1 more source
Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications [PDF]
, 2015 One-fourth of individuals diagnosed with the human immunodeficiency virus concomitantly have the hepatitis C virus infection. Since the discovery of highly active antiretroviral therapy, liver complications have become the leading cause of morbidity and ...
Gandhi, Mona A. +2 more
core +2 more sources
Pharmaceuticals, 2014 Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors.
Ramesh B. Batchu +10 more
doaj +1 more source